ED
EPZM

Exane Derivatives’s Epizyme, Inc EPZM Stock Holding History

Exane Derivatives’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6,800
Closed -$70.1K – 713
2019
Q3 		$70.1K Hold
6,800
– – 0.01% 349
2019
Q2 		$85.3K Hold
6,800
– – 0.02% 346
2019
Q1 		$84.2K Buy
+6,800
New +$76K 0.02% 312

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Exane Derivatives's EPZM Position: Q4 2019 in Review

Exane Derivatives sold out of Epizyme, Inc (EPZM) in Q4 2019, closing a stake of 6,800 shares — an estimated $70.1K sold.

Exane Derivatives first reported a position in EPZM in Q1 2019 and held it in 3 quarters. The position peaked at $85.3K in Q2 2019. 136 funds tracked by Wall St. Rank hold EPZM as of Q4 2019.

  • Exane Derivatives reported no remaining Epizyme, Inc position as of Q4 2019 after selling out during the quarter.
  • Exane Derivatives sold 6,800 Epizyme, Inc shares in Q4 2019, an estimated $70.1K.
  • Exane Derivatives first reported a position in Epizyme, Inc in Q1 2019 and held it in 3 quarters.
  • Exane Derivatives's Epizyme, Inc position peaked at $85.3K in Q2 2019.
  • 136 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2019.

Based on Exane Derivatives's 13F filing for Q4 2019, filed 22 Jan 2020.